HDAC9 and lymphoma: Following the previous attempts to combine BET inhibitors and epigenetic drugs, other combinations, including the BETi RVX2135 and the HDAC inhibitors vorinostat or LBH-589, have also been assessed in MYC-induced murine lymphoma cells, showing a synergistic pro-apoptotic effect, which was believed to rely on BET inhibitors capacity to induce the re-expression of several HDAC-silenced genes [94].